Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature-Reference-Cited by-同舟云学术

Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

Published:2006 Issue: Volume: Page:597-612
ISSN:0076-6879
Container-title:Regulators and Effectors of Small GTPases: Ras Family
language:
Short-container-title:

Author:

Adnane Lila,Trail Pamela A.,Taylor Ian,Wilhelm Scott M.

Publisher

Elsevier

Reference34 articles.

1. Kinase inhibition with BAY 43‐9006 in renal cell carcinoma;Ahmad;Clin. Cancer Res.,2004

2. CI‐1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK);Allen;Semin. Oncol.,2003

3. Dominant negative mutants of mitogen‐activated protein kinase pathway;Arboleda;Methods Enzymol.,2001

4. BRAF and RAS mutations in human lung cancer and melanoma;Brose;Cancer Res.,2002

5. Lack of BRAF mutation in primary uveal melanoma;Cohen;Invest. Ophthalmol. Vis. Sci.,2003

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New modified thieno[2,3-d]pyrimidine derivatives as VEGFR-2 inhibitors: Design, synthesis, in vitro anti-cancer evaluation and divers in silico studies;Journal of Molecular Structure;2024-04

2. Intracellular Ellagic Acid Derived from Goat Urine DMSO Fraction (GUDF) Predicted as an Inhibitor of c-Raf Kinase;Current Molecular Medicine;2024-02

3. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer;Journal of Controlled Release;2024-02

4. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension;Hepatobiliary & Pancreatic Diseases International;2024-02

5. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow;International Journal of Molecular Sciences;2024-01-25